OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial

Burosumab, a fully human IgG1 monoclonal antibody to FGF23, is approved in Canada and Brazil to treat XLH in patients ≥1 year of age and in the US to treat XLH in patients ≥6 months of age. Burosumab has also received conditional marketing authorization in Europe to treat XLH with radiographic evide...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Endocr Soc
Prif Awduron: Perwad, Farzana, Portale, Anthony A, Carpenter, Thomas O, Briot, Karine, Imel, Erik Allen, Kamenicky, Peter, Weber, Thomas Joseph, Pitukcheewanont, Pisit, Cheong, Hae Il, De Beur, Suzanne Marie Jan, Imanishi, Yasuo, Ito, Nobuaki, Lachmann, Robin, Tanaka, Hiroyuki, Zhang, Lin, Skrinar, Alison, Rees, Linda, Insogna, Karl Leonard
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2020
Pynciau:
Bone and Mineral Metabolism
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7209551/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.147
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg